{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T01:41:37Z","timestamp":1773798097324,"version":"3.50.1"},"reference-count":68,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100001422","name":"American Society of Hematology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001422","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.clml.2024.09.008","type":"journal-article","created":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T13:13:44Z","timestamp":1727097224000},"page":"32-44","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Addition of Elotuzumab to Backbone Treatment Regimens for Multiple Myeloma: An Updated Meta-Analysis of Randomized Clinical Trials"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1816-4498","authenticated-orcid":false,"given":"Bruno Almeida","family":"Costa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1789-6694","authenticated-orcid":false,"given":"Thomaz Alexandre","family":"Costa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7398-9070","authenticated-orcid":false,"given":"Gabriel Cavalcante Lima","family":"Chagas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarek H.","family":"Mouhieddine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0274-0585","authenticated-orcid":false,"given":"Joshua","family":"Richter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saad Z.","family":"Usmani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sham","family":"Mailankody","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sridevi","family":"Rajeeve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamza","family":"Hashmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.clml.2024.09.008_bib0001","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","article-title":"Global burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016","volume":"4","author":"Cowan","year":"2018","journal-title":"JAMA Oncol"},{"issue":"8","key":"10.1016\/j.clml.2024.09.008_bib0002","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1016\/j.clml.2024.09.008_bib0003","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.3390\/cancers15082203","article-title":"Current main topics in multiple myeloma","volume":"15","author":"Mor\u00e8","year":"2023","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.clml.2024.09.008_bib0004","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1182\/hematology.2020000109","article-title":"Sequencing multiple myeloma therapies with and after antibody therapies","volume":"2020","author":"van de Donk","year":"2020","journal-title":"Hematol Am Soc Hematol Educ Prog"},{"issue":"6","key":"10.1016\/j.clml.2024.09.008_bib0005","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1182\/blood-2015-10-646810","article-title":"Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma","volume":"127","author":"van de Donk","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2024.09.008_bib0006","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.hoc.2023.12.002","article-title":"Monoclonal antibodies in the treatment of multiple myeloma","volume":"38","author":"van de Donk","year":"2024","journal-title":"Hematol Oncol Clin North Am"},{"issue":"9","key":"10.1016\/j.clml.2024.09.008_bib0007","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1158\/1078-0432.CCR-07-4246","article-title":"CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma","volume":"14","author":"Hsi","year":"2008","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"4","key":"10.1016\/j.clml.2024.09.008_bib0008","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1182\/blood-2007-08-107292","article-title":"Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu","volume":"112","author":"Tai","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2024.09.008_bib0009","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3324\/haematol.2021.279930","article-title":"The efficacy of combination treatment with elotuzumab and lenalidomide is dependent on crosstalk between natural killer cells, monocytes and myeloma cells","volume":"108","author":"Richardson","year":"2023","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.clml.2024.09.008_bib0010","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1182\/blood-2011-06-360552","article-title":"A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma","volume":"120","author":"Zonder","year":"2012","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2024.09.008_bib0011","doi-asserted-by":"crossref","first-page":"e516","DOI":"10.1016\/S2352-3026(15)00197-0","article-title":"Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study","volume":"2","author":"Richardson","year":"2015","journal-title":"Lancet Haematol"},{"issue":"7","key":"10.1016\/j.clml.2024.09.008_bib0012","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.clml.2024.09.008_bib0013","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","article-title":"Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma","volume":"379","author":"Dimopoulos","year":"2018","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.clml.2024.09.008_bib0014","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1182\/blood-2016-01-694604","article-title":"Randomised phase 2 study: elotuzumab plus bortezomib\/dexamethasone vs bortezomib\/dexamethasone for relapsed\/refractory MM","volume":"127","author":"Jakubowiak","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2024.09.008_bib0015","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s40265-016-0540-0","article-title":"Elotuzumab: first global approval","volume":"76","author":"Markham","year":"2016","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.clml.2024.09.008_bib0016","first-page":"67","article-title":"Second elotuzumab triplet efficacious in MM","volume":"16","author":"Killock","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2024.09.008_bib0017","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s12185-019-02757-0","article-title":"Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomised, open-label, phase 2 study in Japan","volume":"111","author":"Kubo","year":"2020","journal-title":"Int J Hematol"},{"issue":"1","key":"10.1016\/j.clml.2024.09.008_bib0018","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1016\/S2352-3026(20)30354-9","article-title":"Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial","volume":"8","author":"Usmani","year":"2021","journal-title":"Lancet Haematol"},{"issue":"6","key":"10.1016\/j.clml.2024.09.008_bib0019","doi-asserted-by":"crossref","first-page":"e403","DOI":"10.1016\/S2352-3026(22)00103-X","article-title":"Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicenter, randomised, phase 3 trial","volume":"9","author":"Dimopoulos","year":"2022","journal-title":"Lancet Haematol"},{"issue":"2","key":"10.1016\/j.clml.2024.09.008_bib0020","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1016\/S2352-3026(23)00366-6","article-title":"Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial","volume":"11","author":"Mai","year":"2024","journal-title":"Lancet Haematol"},{"issue":"16_suppl","key":"10.1016\/j.clml.2024.09.008_bib0021","doi-asserted-by":"crossref","first-page":"8000","DOI":"10.1200\/JCO.2023.41.16_suppl.8000","article-title":"Carfilzomib, lenalidomide, and dexamethasone (KRd) versus elotuzumab and KRd in transplant-eligible patients with newly diagnosed multiple myeloma: post-induction response and MRD results from an open-label randomised phase 3 study","volume":"41","author":"Knop","year":"2023","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.clml.2024.09.008_bib0022","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1001\/jamaoncol.2022.2424","article-title":"Elotuzumab and weekly carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma without transplant intent: a phase 2 measurable residual disease-adapted study","volume":"8","author":"Derman","year":"2022","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.clml.2024.09.008_bib0023","article-title":"Updated guidance for trusted systematic reviews: a new edition of the Cochrane handbook for systematic reviews of interventions","volume":"10","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clml.2024.09.008_bib0024","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.clml.2024.09.008_bib0025","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13045-023-01417-5","article-title":"Treatment outcomes for newly diagnosed, treatment-na\u00efve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis","volume":"16","author":"Daver","year":"2023","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"10.1016\/j.clml.2024.09.008_bib0026","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.clml.2024.09.008_bib0027","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"24","key":"10.1016\/j.clml.2024.09.008_bib0028","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group","volume":"127","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2024.09.008_bib0029","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Using the common terminology criteria for adverse events (CTCAE - Version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas Dermosifiliogr"},{"issue":"2","key":"10.1016\/j.clml.2024.09.008_bib0030","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.cegh.2018.05.005","article-title":"Interpretation of subgroup analyses in systematic reviews: a tutorial","volume":"7","author":"Richardson","year":"2019","journal-title":"Clin Epidemiol Glob Health"},{"issue":"4","key":"10.1016\/j.clml.2024.09.008_bib0031","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2024.09.008_bib0032","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","author":"Facon","year":"2024","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.clml.2024.09.008_bib0033","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/10428194.2023.2284088","article-title":"BCMA-directed therapy, new treatments in the myeloma toolbox, and how to use them","volume":"65","author":"Rees","year":"2024","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"10.1016\/j.clml.2024.09.008_bib0034","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1158\/1535-7163.MCT-09-0483","article-title":"Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma","volume":"8","author":"van Rhee","year":"2009","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"10.1016\/j.clml.2024.09.008_bib0035","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1182\/blood-2007-03-078535","article-title":"Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma","volume":"111","author":"Shi","year":"2008","journal-title":"Blood"},{"issue":"29","key":"10.1016\/j.clml.2024.09.008_bib0036","doi-asserted-by":"crossref","first-page":"26982","DOI":"10.18632\/oncotarget.4831","article-title":"Carfilzomib enhances natural killer cell-mediated lysis of myeloma linked with decreasing expression of HLA class I","volume":"6","author":"Yang","year":"2015","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.clml.2024.09.008_bib0037","first-page":"163","article-title":"Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition","volume":"180","author":"Hallett","year":"2008","journal-title":"J Immunol Baltim Md 1950"},{"issue":"2","key":"10.1016\/j.clml.2024.09.008_bib0038","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1534664","article-title":"Bortezomib sensitizes multiple myeloma to NK cells via ER-stress-induced suppression of HLA-E and upregulation of DR5","volume":"8","author":"Carlsten","year":"2019","journal-title":"Oncoimmunology"},{"issue":"27","key":"10.1016\/j.clml.2024.09.008_bib0039","doi-asserted-by":"crossref","first-page":"23609","DOI":"10.18632\/oncotarget.4603","article-title":"The IMiDs targets IKZF-1\/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma","volume":"6","author":"Fionda","year":"2015","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.clml.2024.09.008_bib0040","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00262-014-1610-3","article-title":"Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-\u03b1 pathways","volume":"64","author":"Balasa","year":"2015","journal-title":"Cancer Immunol Immunother CII"},{"issue":"5","key":"10.1016\/j.clml.2024.09.008_bib0041","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1182\/blood-2010-04-278432","article-title":"The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy","volume":"117","author":"Hsu","year":"2011","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2024.09.008_bib0042","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S2352-3026(21)00283-0","article-title":"Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group","volume":"9","author":"Raje","year":"2022","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.clml.2024.09.008_bib0043","first-page":"228","article-title":"SLAMF7 is a critical negative regulator of IFN-\u03b1-mediated CXCL10 production in chronic HIV infection","volume":"202","author":"O'Connell","year":"2019","journal-title":"J Immunol Baltim Md 1950"},{"issue":"6","key":"10.1016\/j.clml.2024.09.008_bib0044","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1002\/cam4.344","article-title":"G-CSF utilization rate and prescribing patterns in United States: associations between physician and patient factors and GCSF use","volume":"3","author":"Barnes","year":"2014","journal-title":"Cancer Med"},{"key":"10.1016\/j.clml.2024.09.008_bib0045","doi-asserted-by":"crossref","first-page":"5813","DOI":"10.2147\/OTT.S174640","article-title":"Update on elotuzumab for the treatment of relapsed\/refractory multiple myeloma: patients\u2019 selection and perspective","volume":"12","author":"Trudel","year":"2019","journal-title":"OncoTargets Ther"},{"issue":"2","key":"10.1016\/j.clml.2024.09.008_bib0046","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1093\/annonc\/mdw606","article-title":"Second primary malignancies in multiple myeloma: an overview and IMWG consensus","volume":"28","author":"Musto","year":"2017","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"3","key":"10.1016\/j.clml.2024.09.008_bib0047","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1080\/14737140.2023.2169139","article-title":"Safety and efficacy of Elotuzumab combination therapy for patients with multiple myeloma: a systematic review and meta-analysis","volume":"23","author":"Noori","year":"2023","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.clml.2024.09.008_bib0048","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1200\/EDBK_320105","article-title":"How to treat high-risk myeloma at diagnosis and relapse","volume":"41","author":"Caro","year":"2021","journal-title":"Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Annu Meet"},{"issue":"7","key":"10.1016\/j.clml.2024.09.008_bib0049","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.18632\/oncotarget.1049","article-title":"Plasma membrane proteomics identifies biomarkers associated with MMSET overexpression in T(4;14) multiple myeloma","volume":"4","author":"Xie","year":"2013","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.clml.2024.09.008_bib0050","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41375-019-0525-6","article-title":"Soluble SLAMF7 promotes the growth of myeloma cells via homophilic interaction with surface SLAMF7","volume":"34","author":"Kikuchi","year":"2020","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.clml.2024.09.008_bib0051","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clml.2024.09.008_bib0052","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.clml.2024.09.008_bib0053","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.clml.2021.10.013","article-title":"Comparison of Cilta-cel, an Anti-BCMA CAR-T cell therapy, versus conventional treatment in patients with relapsed\/refractory multiple myeloma","volume":"22","author":"Costa","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.09.008_bib0054","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1182\/blood-2023-182130","article-title":"Long-term efficacy and safety of elranatamab monotherapy in the phase 2 magnetismm-3 trial in relapsed or refractory multiple myeloma (RRMM)","volume":"142","author":"Tomasson","year":"2023","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.clml.2024.09.008_bib0055","doi-asserted-by":"crossref","first-page":"8011","DOI":"10.1200\/JCO.2023.41.16_suppl.8011","article-title":"Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"41","author":"Van De Donk","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2024.09.008_bib0056","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa2405090","article-title":"Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma","volume":"391","author":"Hungria","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2024.09.008_bib0057","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa2403407","article-title":"Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma","volume":"391","author":"Dimopoulos","year":"2024","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.clml.2024.09.008_bib0058","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41408-022-00695-5","article-title":"Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: consensus recommendations of the NCI multiple myeloma steering committee","volume":"12","author":"Kumar","year":"2022","journal-title":"Blood Cancer J"},{"issue":"11","key":"10.1016\/j.clml.2024.09.008_bib0059","first-page":"1628","article-title":"Novel immunotherapies and combinations: the future landscape of multiple myeloma treatment","volume":"16","author":"Mor\u00e8","year":"2023","journal-title":"Pharm Basel Switz"},{"key":"10.1016\/j.clml.2024.09.008_bib0060","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1200\/EDBK_200841","article-title":"Global approaches in myeloma: critical trials that may change practice","volume":"38","author":"Moreau","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Annu Meet"},{"issue":"19","key":"10.1016\/j.clml.2024.09.008_bib0061","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1182\/blood.2020008734","article-title":"How I treat relapsed multiple myeloma","volume":"139","author":"Kastritis","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.09.008_bib0062","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/EDBK_205443","article-title":"Practical considerations for antibodies in myeloma","volume":"38","author":"Laubach","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Annu Meet"},{"issue":"1","key":"10.1016\/j.clml.2024.09.008_bib0063","first-page":"245","article-title":"Elotuzumab plus pomalidomide and dexamethasone in relapsed\/refractory multiple myeloma: a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trials","volume":"109","author":"Gentile","year":"2024","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.clml.2024.09.008_bib0064","doi-asserted-by":"crossref","first-page":"5159","DOI":"10.1038\/s41598-023-32426-6","article-title":"Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa\/lambda ratio or B2 microglobulin","volume":"13","author":"Shimazu","year":"2023","journal-title":"Sci Rep."},{"issue":"6","key":"10.1016\/j.clml.2024.09.008_bib0065","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3892\/ol.2024.14381","article-title":"Daratumumab\u2011resistant multiple myeloma with extramedullary disease successfully treated with combination elotuzumab, pomalidomide and dexamethasone: a case report","volume":"27","author":"Sakashita","year":"2024","journal-title":"Oncol Lett"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.09.008_bib0066","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1182\/blood-2020-142923","article-title":"Clinical outcomes in relapsed\/refractory multiple myeloma patients receiving sequential elotuzumab and daratumumab: a single center experience","volume":"136","author":"Basher","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.09.008_bib0067","article-title":"Efficacy of elotuzumab for multiple myeloma deteriorates after daratumumab: a multicenter retrospective study","volume":"16","author":"Nakamura","year":"2024","journal-title":"Ann Hematol"},{"issue":"11","key":"10.1016\/j.clml.2024.09.008_bib0068","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1001\/jamaoncol.2020.4338","article-title":"Evaluation of daratumumab for the treatment of multiple myeloma in patients with high-risk cytogenetic factors: a systematic review and meta-analysis","volume":"6","author":"Giri","year":"2020","journal-title":"JAMA Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024023528?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024023528?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T06:39:28Z","timestamp":1736059168000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024023528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S2152265024023528"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.09.008","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Addition of Elotuzumab to Backbone Treatment Regimens for Multiple Myeloma: An Updated Meta-Analysis of Randomized Clinical Trials","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}